Tuesday, March 17, 2026

SJN314: The Promising New Immunotherapy for Chronic Inflammatory Diseases in Asia

Samjin Pharmaceutical submits phase 1 trial plan for SJN314, targeting immune diseases, aiming for global partnerships in early clinical phases.

Kim Yo-jong Rejoins North Korea’s Power Circle: What This Means for the Regime

Kim Yo-jong returns to North Korea's Politburo as an alternate member after five years, influencing external strategy but not fully promoted.

Batteries for the AI Era: Samsung SDI’s Big Reveal at InterBattery 2025

Samsung SDI will showcase innovative batteries at InterBattery Europe 2025, focusing on energy storage for the AI era.

How AI is Changing the Game for Drug Makers!

TechHow AI is Changing the Game for Drug Makers!
News1

The Ministry of Science and ICT and the Ministry of Health and Welfare of South Korea announced today that 26 projects have been selected for the Federated Learning-Based New Drug Development Acceleration Project and officially launched the initiative.

Federated learning is a decentralized method that enables institutions to analyze data without sharing it directly. Institutions perform internal analyses and send only the results to a central server, ensuring data privacy while still benefiting from the analysis.

This joint initiative aims to reduce the costs and time associated with new drug development using AI models based on federated learning.

Since its inception in April, the project team has chosen 26 specific tasks in three areas through a competitive application process: Federated Learning Platform Construction, Utilization and Quality Management of New Drug Development Data, and AI Solution Development.

The Ministry of Science and ICT and the Ministry of Health and Welfare will fund the research projects with a $26 million budget over five years, extending to 2028.

Kwon Hyun Jun, Director of Basic Research Policy at the Ministry of Science and ICT, expressed optimism about the project. He said, “We anticipate that the high-quality new drug development data accumulated by various institutions will be safely utilized, leading to the development of robust AI-based drug development platforms and solutions.”

Go Hyung Woo, Director of Advanced Medical Support at the Ministry of Health and Welfare, added, “We will actively support AI and data R&D to drive innovations in future healthcare and pharmaceuticals while contributing to improving public health.”

Check Out Our Content

Check Out Other Tags:

Most Popular Articles